APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-Oncology Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Immuno-Oncology Service Market Analysis and Forecast 2026-2032

5 June 2026204 pages

Choose your research edition.

Industry ResearchImmuno-Oncology Service Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-Oncology Service Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Immuno-Oncology Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-Oncology Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-Oncology Service Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Immuno-Oncology Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Immuno-Oncology Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Immuno-Oncology Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Immuno-Oncology Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Immuno-Oncology Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Immuno-Oncology Service include Crown Bioscience, Bio-Techne, Abcam, WuXi AppTec, Shanghai ChemPartner, George Clinical, Laboratory Corporation of America® Holdings, Medpace and Genscript, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Immuno-Oncology Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immuno-Oncology Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Immuno-Oncology Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immuno-Oncology Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immuno-Oncology Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Immuno-Oncology Service revenue, projected growth trends, production technology, application and end-user industry.

Immuno-Oncology Service Segment by Company

Crown Bioscience

Bio-Techne

Abcam

WuXi AppTec

Shanghai ChemPartner

George Clinical

Laboratory Corporation of America® Holdings

Medpace

Genscript

Shanghai Novamab Biopharmaceuticals

LIDE

TransCure bioServices

Immuno-Oncology Service Segment by Type

Basic Research

Clinical Research

Immuno-Oncology Service Segment by Application

Pharmaceutical Companies

Medical Device Companies

Other

Immuno-Oncology Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Immuno-Oncology Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Immuno-Oncology Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-Oncology Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immuno-Oncology Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Basic Research Major Player Table 3. Clinical Research Major Player Table 4. Global Immuno-Oncology Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical Companies Major Player Table 6. Medical Device Companies Major Player Table 7. Other Major Player Table 8. Immuno-Oncology Service Industry Trends Table 9. Immuno-Oncology Service Industry Drivers Table 10. Immuno-Oncology Service Industry Opportunities and Challenges Table 11. Immuno-Oncology Service Industry Restraints Table 12. Global Immuno-Oncology Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Immuno-Oncology Service Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Immuno-Oncology Service Market Share by Region (2021-2026) Table 15. Global Immuno-Oncology Service Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Immuno-Oncology Service Market Share by Region (2027-2032) Table 17. Global Immuno-Oncology Service Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Immuno-Oncology Service Revenue Market Share by Players (2021-2026) Table 19. Global Immuno-Oncology Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Immuno-Oncology Service Key Players Headquarters & Area Served Table 21. Global Immuno-Oncology Service Players, Product Type & Application Table 22. Global Immuno-Oncology Service Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Immuno-Oncology Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Immuno-Oncology Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Immuno-Oncology Service Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Immuno-Oncology Service Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Immuno-Oncology Service Revenue Market Share by Type (2021-2026) Table 29. Global Immuno-Oncology Service Revenue Market Share by Type (2027-2032) Table 30. Global Immuno-Oncology Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Immuno-Oncology Service Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Immuno-Oncology Service Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Immuno-Oncology Service Revenue Market Share by Application (2021-2026) Table 34. Global Immuno-Oncology Service Revenue Market Share by Application (2027-2032) Table 35. Crown Bioscience Company Information Table 36. Crown Bioscience Business Overview Table 37. Crown Bioscience Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Crown Bioscience Immuno-Oncology Service Product Portfolio Table 39. Crown Bioscience Recent Development Table 40. Bio-Techne Company Information Table 41. Bio-Techne Business Overview Table 42. Bio-Techne Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Bio-Techne Immuno-Oncology Service Product Portfolio Table 44. Bio-Techne Recent Development Table 45. Abcam Company Information Table 46. Abcam Business Overview Table 47. Abcam Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Abcam Immuno-Oncology Service Product Portfolio Table 49. Abcam Recent Development Table 50. WuXi AppTec Company Information Table 51. WuXi AppTec Business Overview Table 52. WuXi AppTec Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. WuXi AppTec Immuno-Oncology Service Product Portfolio Table 54. WuXi AppTec Recent Development Table 55. Shanghai ChemPartner Company Information Table 56. Shanghai ChemPartner Business Overview Table 57. Shanghai ChemPartner Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Shanghai ChemPartner Immuno-Oncology Service Product Portfolio Table 59. Shanghai ChemPartner Recent Development Table 60. George Clinical Company Information Table 61. George Clinical Business Overview Table 62. George Clinical Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. George Clinical Immuno-Oncology Service Product Portfolio Table 64. George Clinical Recent Development Table 65. Laboratory Corporation of America® Holdings Company Information Table 66. Laboratory Corporation of America® Holdings Business Overview Table 67. Laboratory Corporation of America® Holdings Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Laboratory Corporation of America® Holdings Immuno-Oncology Service Product Portfolio Table 69. Laboratory Corporation of America® Holdings Recent Development Table 70. Medpace Company Information Table 71. Medpace Business Overview Table 72. Medpace Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Medpace Immuno-Oncology Service Product Portfolio Table 74. Medpace Recent Development Table 75. Genscript Company Information Table 76. Genscript Business Overview Table 77. Genscript Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Genscript Immuno-Oncology Service Product Portfolio Table 79. Genscript Recent Development Table 80. Shanghai Novamab Biopharmaceuticals Company Information Table 81. Shanghai Novamab Biopharmaceuticals Business Overview Table 82. Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Product Portfolio Table 84. Shanghai Novamab Biopharmaceuticals Recent Development Table 85. LIDE Company Information Table 86. LIDE Business Overview Table 87. LIDE Immuno-Oncology Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. LIDE Immuno-Oncology Service Product Portfolio Table 89. LIDE Recent Development Table 90. TransCure bioServices Company Information Table 91. TransCure bioServices Business Overview Table 92. TransCure bioServices Immuno-Oncology Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. TransCure bioServices Immuno-Oncology Service Product Portfolio Table 94. TransCure bioServices Recent Development Table 95. North America Immuno-Oncology Service Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Immuno-Oncology Service Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Immuno-Oncology Service Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Immuno-Oncology Service Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Immuno-Oncology Service Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Immuno-Oncology Service Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Immuno-Oncology Service Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Immuno-Oncology Service Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Immuno-Oncology Service Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Immuno-Oncology Service Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Immuno-Oncology Service Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Immuno-Oncology Service Revenue by Country (US$ Million) & (2027-2032) Table 109. China Immuno-Oncology Service Revenue by Type (2021-2026) & (US$ Million) Table 110. China Immuno-Oncology Service Revenue by Type (2027-2032) & (US$ Million) Table 111. China Immuno-Oncology Service Revenue by Application (2021-2026) & (US$ Million) Table 112. China Immuno-Oncology Service Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Immuno-Oncology Service Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Immuno-Oncology Service Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Immuno-Oncology Service Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Immuno-Oncology Service Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Immuno-Oncology Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Immuno-Oncology Service Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Immuno-Oncology Service Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Immuno-Oncology Service Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Immuno-Oncology Service Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Immuno-Oncology Service Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Immuno-Oncology Service Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Immuno-Oncology Service Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Immuno-Oncology Service Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Immuno-Oncology Service Image Figure 2. Global Immuno-Oncology Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immuno-Oncology Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Basic Research Image Figure 5. Clinical Research Image Figure 6. Global Immuno-Oncology Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Immuno-Oncology Service Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical Companies Image Figure 9. Medical Device Companies Image Figure 10. Other Image Figure 11. Global Immuno-Oncology Service Market Size (US$ Million) & (2021-2032) Figure 12. Global Immuno-Oncology Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Immuno-Oncology Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Immuno-Oncology Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Immuno-Oncology Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Immuno-Oncology Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Immuno-Oncology Service Revenue Market Share by Type (2021-2032) Figure 19. Global Immuno-Oncology Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Immuno-Oncology Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Immuno-Oncology Service Revenue Market Share by Application (2021-2032) Figure 22. North America Immuno-Oncology Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Immuno-Oncology Service Revenue Share by Type (2021-2032) Figure 24. North America Immuno-Oncology Service Revenue Share by Application (2021-2032) Figure 25. North America Immuno-Oncology Service Revenue Share by Country (2021-2032) Figure 26. United States Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Immuno-Oncology Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Immuno-Oncology Service Revenue Share by Type (2021-2032) Figure 31. Europe Immuno-Oncology Service Revenue Share by Application (2021-2032) Figure 32. Europe Immuno-Oncology Service Revenue Share by Country (2021-2032) Figure 33. Germany Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Immuno-Oncology Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Immuno-Oncology Service Revenue Share by Type (2021-2032) Figure 43. China Immuno-Oncology Service Revenue Share by Application (2021-2032) Figure 44. Asia Immuno-Oncology Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Immuno-Oncology Service Revenue Share by Type (2021-2032) Figure 46. Asia Immuno-Oncology Service Revenue Share by Application (2021-2032) Figure 47. Asia Immuno-Oncology Service Revenue Share by Region (2021-2032) Figure 48. Japan Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Immuno-Oncology Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Immuno-Oncology Service Revenue Share by Type (2021-2032) Figure 56. SAMEA Immuno-Oncology Service Revenue Share by Application (2021-2032) Figure 57. SAMEA Immuno-Oncology Service Revenue Share by Country (2021-2032) Figure 58. Brazil Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Immuno-Oncology Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Basic Research
  • Clinical Research
Applications
  • Pharmaceutical Companies
  • Medical Device Companies
  • Other
Companies covered
  • Crown Bioscience
  • Bio-Techne
  • Abcam
  • WuXi AppTec
  • Shanghai ChemPartner
  • George Clinical
  • Laboratory Corporation of America® Holdings
  • Medpace
  • Genscript
  • Shanghai Novamab Biopharmaceuticals
  • LIDE
  • TransCure bioServices

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immuno-Oncology Service Market by Type
  3. 1.2.1 Global Immuno-Oncology Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Basic Research
  5. 1.2.3 Clinical Research
  6. 1.3 Immuno-Oncology Service Market by Application
  7. 1.3.1 Global Immuno-Oncology Service Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical Companies
  9. 1.3.3 Medical Device Companies
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Immuno-Oncology Service Market Dynamics
  1. 2.1 Immuno-Oncology Service Industry Trends
  2. 2.2 Immuno-Oncology Service Industry Drivers
  3. 2.3 Immuno-Oncology Service Industry Opportunities and Challenges
  4. 2.4 Immuno-Oncology Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Immuno-Oncology Service Market Perspective (2021-2032)
  2. 3.2 Global Immuno-Oncology Service Growth Trends by Region
  3. 3.2.1 Global Immuno-Oncology Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immuno-Oncology Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Immuno-Oncology Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Immuno-Oncology Service Revenue by Players
  2. 4.1.1 Global Immuno-Oncology Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Immuno-Oncology Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Immuno-Oncology Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immuno-Oncology Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Immuno-Oncology Service Key Players Headquarters & Area Served
  7. 4.4 Global Immuno-Oncology Service Players, Product Type & Application
  8. 4.5 Global Immuno-Oncology Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Immuno-Oncology Service Market CR5 and HHI
  11. 4.6.3 2025 Immuno-Oncology Service Tier 1, Tier 2, and Tier 3
5 Immuno-Oncology Service Market Size by Type
  1. 5.1 Global Immuno-Oncology Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Immuno-Oncology Service Revenue by Type (2021-2032)
  3. 5.3 Global Immuno-Oncology Service Revenue Market Share by Type (2021-2032)
6 Immuno-Oncology Service Market Size by Application
  1. 6.1 Global Immuno-Oncology Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Immuno-Oncology Service Revenue by Application (2021-2032)
  3. 6.3 Global Immuno-Oncology Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Crown Bioscience
  2. 7.1.1 Crown Bioscience Company Information
  3. 7.1.2 Crown Bioscience Business Overview
  4. 7.1.3 Crown Bioscience Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Crown Bioscience Immuno-Oncology Service Product Portfolio
  6. 7.1.5 Crown Bioscience Recent Developments
  7. 7.2 Bio-Techne
  8. 7.2.1 Bio-Techne Company Information
  9. 7.2.2 Bio-Techne Business Overview
  10. 7.2.3 Bio-Techne Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bio-Techne Immuno-Oncology Service Product Portfolio
  12. 7.2.5 Bio-Techne Recent Developments
  13. 7.3 Abcam
  14. 7.3.1 Abcam Company Information
  15. 7.3.2 Abcam Business Overview
  16. 7.3.3 Abcam Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Abcam Immuno-Oncology Service Product Portfolio
  18. 7.3.5 Abcam Recent Developments
  19. 7.4 WuXi AppTec
  20. 7.4.1 WuXi AppTec Company Information
  21. 7.4.2 WuXi AppTec Business Overview
  22. 7.4.3 WuXi AppTec Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 WuXi AppTec Immuno-Oncology Service Product Portfolio
  24. 7.4.5 WuXi AppTec Recent Developments
  25. 7.5 Shanghai ChemPartner
  26. 7.5.1 Shanghai ChemPartner Company Information
  27. 7.5.2 Shanghai ChemPartner Business Overview
  28. 7.5.3 Shanghai ChemPartner Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Shanghai ChemPartner Immuno-Oncology Service Product Portfolio
  30. 7.5.5 Shanghai ChemPartner Recent Developments
  31. 7.6 George Clinical
  32. 7.6.1 George Clinical Company Information
  33. 7.6.2 George Clinical Business Overview
  34. 7.6.3 George Clinical Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 George Clinical Immuno-Oncology Service Product Portfolio
  36. 7.6.5 George Clinical Recent Developments
  37. 7.7 Laboratory Corporation of America® Holdings
  38. 7.7.1 Laboratory Corporation of America® Holdings Company Information
  39. 7.7.2 Laboratory Corporation of America® Holdings Business Overview
  40. 7.7.3 Laboratory Corporation of America® Holdings Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Laboratory Corporation of America® Holdings Immuno-Oncology Service Product Portfolio
  42. 7.7.5 Laboratory Corporation of America® Holdings Recent Developments
  43. 7.8 Medpace
  44. 7.8.1 Medpace Company Information
  45. 7.8.2 Medpace Business Overview
  46. 7.8.3 Medpace Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Medpace Immuno-Oncology Service Product Portfolio
  48. 7.8.5 Medpace Recent Developments
  49. 7.9 Genscript
  50. 7.9.1 Genscript Company Information
  51. 7.9.2 Genscript Business Overview
  52. 7.9.3 Genscript Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Genscript Immuno-Oncology Service Product Portfolio
  54. 7.9.5 Genscript Recent Developments
  55. 7.10 Shanghai Novamab Biopharmaceuticals
  56. 7.10.1 Shanghai Novamab Biopharmaceuticals Company Information
  57. 7.10.2 Shanghai Novamab Biopharmaceuticals Business Overview
  58. 7.10.3 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Product Portfolio
  60. 7.10.5 Shanghai Novamab Biopharmaceuticals Recent Developments
  61. 7.11 LIDE
  62. 7.11.1 LIDE Company Information
  63. 7.11.2 LIDE Business Overview
  64. 7.11.3 LIDE Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 LIDE Immuno-Oncology Service Product Portfolio
  66. 7.11.5 LIDE Recent Developments
  67. 7.12 TransCure bioServices
  68. 7.12.1 TransCure bioServices Company Information
  69. 7.12.2 TransCure bioServices Business Overview
  70. 7.12.3 TransCure bioServices Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 TransCure bioServices Immuno-Oncology Service Product Portfolio
  72. 7.12.5 TransCure bioServices Recent Developments
8 North America
  1. 8.1 North America Immuno-Oncology Service Revenue (2021-2032)
  2. 8.2 North America Immuno-Oncology Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Immuno-Oncology Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Immuno-Oncology Service Revenue by Type (2027-2032)
  5. 8.3 North America Immuno-Oncology Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Immuno-Oncology Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Immuno-Oncology Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Immuno-Oncology Service Revenue by Application (2027-2032)
  9. 8.5 North America Immuno-Oncology Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Immuno-Oncology Service Revenue by Country
  11. 8.6.1 North America Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Immuno-Oncology Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Immuno-Oncology Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Immuno-Oncology Service Revenue (2021-2032)
  2. 9.2 Europe Immuno-Oncology Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Immuno-Oncology Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Immuno-Oncology Service Revenue by Type (2027-2032)
  5. 9.3 Europe Immuno-Oncology Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Immuno-Oncology Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Immuno-Oncology Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Immuno-Oncology Service Revenue by Application (2027-2032)
  9. 9.5 Europe Immuno-Oncology Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Immuno-Oncology Service Revenue by Country
  11. 9.6.1 Europe Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Immuno-Oncology Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Immuno-Oncology Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Immuno-Oncology Service Revenue (2021-2032)
  2. 10.2 China Immuno-Oncology Service Revenue by Type (2021-2032)
  3. 10.2.1 China Immuno-Oncology Service Revenue by Type (2021-2026)
  4. 10.2.2 China Immuno-Oncology Service Revenue by Type (2027-2032)
  5. 10.3 China Immuno-Oncology Service Revenue Share by Type (2021-2032)
  6. 10.4 China Immuno-Oncology Service Revenue by Application (2021-2032)
  7. 10.4.1 China Immuno-Oncology Service Revenue by Application (2021-2026)
  8. 10.4.2 China Immuno-Oncology Service Revenue by Application (2027-2032)
  9. 10.5 China Immuno-Oncology Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immuno-Oncology Service Revenue (2021-2032)
  2. 11.2 Asia Immuno-Oncology Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Immuno-Oncology Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Immuno-Oncology Service Revenue by Type (2027-2032)
  5. 11.3 Asia Immuno-Oncology Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Immuno-Oncology Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Immuno-Oncology Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Immuno-Oncology Service Revenue by Application (2027-2032)
  9. 11.5 Asia Immuno-Oncology Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Immuno-Oncology Service Revenue by Country
  11. 11.6.1 Asia Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Immuno-Oncology Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Immuno-Oncology Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immuno-Oncology Service Revenue (2021-2032)
  2. 12.2 SAMEA Immuno-Oncology Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Immuno-Oncology Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Immuno-Oncology Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Immuno-Oncology Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Immuno-Oncology Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Immuno-Oncology Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Immuno-Oncology Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Immuno-Oncology Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Immuno-Oncology Service Revenue by Country
  11. 12.6.1 SAMEA Immuno-Oncology Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Immuno-Oncology Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Immuno-Oncology Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst